Trial Profile
A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Celgene Corporation; Pharmion Corporation
- 02 Mar 2009 Results reported in the Journal of Clinical Oncology.
- 23 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov. The actual completion date was September 2008.
- 22 Sep 2008 Celgene Corporations added as an Affiliate and Sponsor, reported by Clinicaltrials.gov.